These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 29279926)

  • 1. Guselkumab (Tremfya) for Psoriasis.
    JAMA; 2017 Dec; 318(24):2487-2488. PubMed ID: 29279926
    [No Abstract]   [Full Text] [Related]  

  • 2. Guselkumab for plaque psoriasis.
    Aust Prescr; 2019 Jun; 42(3):105-106. PubMed ID: 31363311
    [No Abstract]   [Full Text] [Related]  

  • 3. Guselkumab (an IL-23-specific mAb) demonstrates clinical and molecular response in patients with moderate-to-severe psoriasis.
    Sofen H; Smith S; Matheson RT; Leonardi CL; Calderon C; Brodmerkel C; Li K; Campbell K; Marciniak SJ; Wasfi Y; Wang Y; Szapary P; Krueger JG
    J Allergy Clin Immunol; 2014 Apr; 133(4):1032-40. PubMed ID: 24679469
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Phase 2 Trial of Guselkumab versus Adalimumab for Plaque Psoriasis.
    Gordon KB; Duffin KC; Bissonnette R; Prinz JC; Wasfi Y; Li S; Shen YK; Szapary P; Randazzo B; Reich K
    N Engl J Med; 2015 Jul; 373(2):136-44. PubMed ID: 26154787
    [TBL] [Abstract][Full Text] [Related]  

  • 5. First-in-human study to assess guselkumab (anti-IL-23 mAb) pharmacokinetics/safety in healthy subjects and patients with moderate-to-severe psoriasis.
    Zhuang Y; Calderon C; Marciniak SJ; Bouman-Thio E; Szapary P; Yang TY; Schantz A; Davis HM; Zhou H; Xu Z
    Eur J Clin Pharmacol; 2016 Nov; 72(11):1303-1310. PubMed ID: 27515978
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo- and active comparator-controlled VOYAGE 2 trial.
    Reich K; Armstrong AW; Foley P; Song M; Wasfi Y; Randazzo B; Li S; Shen YK; Gordon KB
    J Am Acad Dermatol; 2017 Mar; 76(3):418-431. PubMed ID: 28057361
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator-controlled VOYAGE 1 trial.
    Blauvelt A; Papp KA; Griffiths CE; Randazzo B; Wasfi Y; Shen YK; Li S; Kimball AB
    J Am Acad Dermatol; 2017 Mar; 76(3):405-417. PubMed ID: 28057360
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Review of Guselkumab, an IL-23 Inhibitor, for Moderate-to-Severe Plaque Psoriasis.
    Nawas Z; Hatch M; Ramos E; Liu M; Tong Y; Peranteau A; Tyring S
    Skin Therapy Lett; 2017 Mar; 22(2):8-10. PubMed ID: 28329405
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of emerging immunotherapies in psoriasis.
    Yiu ZZ; Warren RB
    Immunotherapy; 2015; 7(2):119-33. PubMed ID: 25713988
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New biologics in psoriasis: an update on IL-23 and IL-17 inhibitors.
    Dong J; Goldenberg G
    Cutis; 2017 Feb; 99(2):123-127. PubMed ID: 28319618
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of interleukin-17, interleukin-23 and the TH17 cell pathway in the treatment of psoriatic arthritis and psoriasis.
    Mease PJ
    Curr Opin Rheumatol; 2015 Mar; 27(2):127-33. PubMed ID: 25599143
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Forms of expression of pustular psoriasis; differentiation of psoriasis cum pustulatione from psoriasis pustulosa of the Zumbusch type].
    SCHUPPENER HJ
    Dermatol Wochenschr; 1958 Aug; 138(31):841-54. PubMed ID: 13585878
    [No Abstract]   [Full Text] [Related]  

  • 13. [Psoriasis (psoriasis vulgaris). 1. Description of the clinical pictures, etiology and complications of psoriasis].
    Lubach D
    Krankenpfl J; 1983 Jul; 21(7-8):31-4. PubMed ID: 6555432
    [No Abstract]   [Full Text] [Related]  

  • 14. Psoriasis rupioides: a rare variant of a common disease.
    Salamon M; Omulecki A; Sysa-Jedrzejowska A; McCauliffe DP; Woźniacka A
    Cutis; 2011 Sep; 88(3):135-7. PubMed ID: 22017066
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Depression and psoriasis].
    Misery L
    Ann Dermatol Venereol; 2012 Apr; 139 Suppl 2():S53-7. PubMed ID: 22541729
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Psoriasis: Pathogenesis, Assessment, and Therapeutic Update.
    Schleicher SM
    Clin Podiatr Med Surg; 2016 Jul; 33(3):355-66. PubMed ID: 27215156
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Systemic retinoids for psoriasis.
    Wieder JM; Lowe NJ
    Dermatol Clin; 1995 Oct; 13(4):891-6. PubMed ID: 8785892
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Linear psoriasis.
    Chien P; Rosenman K; Cheung W; Wang N; Sanchez M
    Dermatol Online J; 2009 Aug; 15(8):4. PubMed ID: 19891912
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Factors associated with quality of life among patients with psoriasis. Comparison between psoriasis-specific QOL measures and generic QOL measures].
    Hirabe M; Hasegawa T; Fujishiro Y; Kigawa M; Fukuchi O; Nakagawa H
    Nihon Koshu Eisei Zasshi; 2008 Feb; 55(2):65-74. PubMed ID: 18404887
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Infliximab associated new-onset psoriasis.
    Adams DR; Buckel T; Sceppa JA
    J Drugs Dermatol; 2006 Feb; 5(2):178-9. PubMed ID: 16485887
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.